cefotaxime
cefotaxime structure
|
Common Name | cefotaxime | ||
|---|---|---|---|---|
| CAS Number | 63527-52-6 | Molecular Weight | 455.466 | |
| Density | 1.8±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C16H17N5O7S2 | Melting Point | 162-163℃ | |
| MSDS | N/A | Flash Point | N/A | |
Use of cefotaximeCefotaxime, a third-generation cephalosporin antibiotic, possesses broad-spectrum antibiotic activity against numerous Gram-positive and Gram-negative bacteria[1][2][3][4]. |
| Name | cefotaxime |
|---|---|
| Synonym | More Synonyms |
| Description | Cefotaxime, a third-generation cephalosporin antibiotic, possesses broad-spectrum antibiotic activity against numerous Gram-positive and Gram-negative bacteria[1][2][3][4]. |
|---|---|
| Related Catalog | |
| In Vitro | Cefotaxime exhibits an MIC of 0.0625 mg/L for V. vulnificus CMCP6[4]. |
| In Vivo | The combination of ciprofloxacin and cefotaxime is more effective in clearing V. vulnificus in vivo than previously used regimens[4]. Animal Model: Female, specific pathogen free, 8-week-old BALB/c mice[4]. Dosage: 30 mg/kg. Administration: IP every 6 h. Result: The viable bacterial counts in liver were lower in mice treated with cefotaxime-plus-ciprofloxacin than in those treated with cefotaxime alone (P<0.001 at 24 h and 48 h, each). |
| References |
| Density | 1.8±0.1 g/cm3 |
|---|---|
| Melting Point | 162-163℃ |
| Molecular Formula | C16H17N5O7S2 |
| Molecular Weight | 455.466 |
| Exact Mass | 455.056946 |
| PSA | 227.05000 |
| LogP | 1.20 |
| Index of Refraction | 1.779 |
| Storage condition | 2-8℃ |
| HS Code | 3003201100 |
|---|
| Precursor 8 | |
|---|---|
| DownStream 5 | |
![(6R,7R)-3-(acetyloxymethyl)-7-[[(2E)-2-[2-[(2-chloroacetyl)amino]-1,3-thiazol-4-yl]-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Structure](https://image.chemsrc.com/caspic/131/64486-19-7.png)
CAS#:64486-19-7![(6R,7R)-3-(acetoxymethyl)-7-(4-chloro-2-(methoxyimino)-3-oxobutanamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Structure](https://image.chemsrc.com/caspic/037/71754-15-9.png)
CAS#:71754-15-9
CAS#:80756-85-0
CAS#:957-68-6
CAS#:111230-59-2
CAS#:64485-88-7
CAS#:65872-39-1![ethyl (2Z)-2-methoxyimino-2-[2-(tritylamino)-1,3-thiazol-4-yl]acetate Structure](https://image.chemsrc.com/caspic/018/64485-89-8.png)
CAS#:64485-89-8
CAS#:80370-57-6
CAS#:87239-81-4
CAS#:84957-29-9
CAS#:84957-30-2
CAS#:64485-93-4| HS Code | 3003201100 |
|---|
|
Effects of decontamination of the digestive tract and oropharynx in intensive care unit patients on 1-year survival.
Am. J. Respir. Crit. Care Med. 188(1) , 117-20, (2013)
|
|
|
National surveillance study on carbapenem non-susceptible Klebsiella pneumoniae in Taiwan: the emergence and rapid dissemination of KPC-2 carbapenemase.
PLoS ONE 8(7) , e69428, (2013) The global spread and increasing incidence of carbapenem non-susceptible Klebsiella pneumoniae (CnSKP) has made its treatment difficult, increasing the mortality. To establish nationwide data on CnSKP... |
|
|
Synthesis, characterization, and antimicrobial activity of poly(acrylonitrile-co-methyl methacrylate) with silver nanoparticles.
Appl. Biochem. Biotechnol. 171(3) , 643-54, (2013) Nanotechnology is expected to open some new aspects to fight and prevent diseases using atomic-scale tailoring of materials. The main aim of this study is to biosynthesize silver nanoparticles (AgNPs)... |
| 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[(acetyloxy)methyl]-7-[[2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-8-oxo-, (6R,7R)- |
| Cefotaxime |
| (6R,7R)-3-(Acetoxymethyl)-7-{[(2-amino-1,3-thiazol-4-yl)(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| Zariviz |
| Cefabol |
| Cefotaxima acid |
| EINECS 264-299-1 |
| Cephotaxime |